TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06333639

Intervention type: OTHER
Intervention: orthopaedic surgery and fitted with a virtual reality headset
Description: usual procedures for an orthopaedic surgery and fitted with a virtual reality headset
Study: NCT05665868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: integrated care mode
Description: The information system consists of big data platform and nursing strategy platform. The system includes medical work end, patient operation end and administrator management end. The big data platform can automatically extract patient data from HIS, Medcare and other patient diagnosis and treatment systems, complete registration and establish patient health files according to the preset patient registration standards. By comparing the data input on the patient side with the database set on the platform, the system decision-making module can generate personalized measures and plans for feedback to patients, and can generate patient information overview feedback to the nurse side. Complete intelligent push of symptom management decision model

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional care mode
Description: ① The health education manual for patients receiving targeted treatment of gastric stromal tumors will be issued. The patients who need targeted treatment will be identified and followed up in the routine outpatient department (1 month, 3 months, 6 months, 12 months after surgery, and once a year thereafter); ② Telephone follow-up (1 month, 3 months, 6 months, 12 months and once a year thereafter); ③ Patients independently complete disease symptom monitoring, lifestyle adjustment, and other disease self-management.
Study: NCT04440501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Goggles to provide education a regarding the gluten free diet.
Description: To watch and participate in a virtual reality educational experience regarding the gluten free diet.
Study: NCT06514352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin contact immediately after birth
Description: In the immediate skin-to-skin contact group after birth, if the newborn does not need any intervention, he will be placed on the mother's chest immediately (without cord clamping) and skin-to-skin contact will begin. An average of 60 minutes of skin contact will be made until the first breastfeeding occurs. All routine practices for the newborn in the delivery room (except weight measurement) will be performed on the mother's chest. (n=48)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Early Skin contact
Description: In the very early skin-to-skin contact group, skin-to-skin contact will begin within the first 30-40 minutes after birth, after the first and emergency intervention is given to the newborn in need of intervention, and skin-to-skin contact will be carried out for an average of 60 minutes until the first breastfeeding occurs.(n=48)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Skin contact
Description: For newborns who need intervention after birth and whose skin-to-skin contact cannot be started in the delivery room, skin-to-skin contact will begin within the first 24 hours after birth, after the newborn becomes stable.(n=48)
Study: NCT04746638

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: whole body study and SPECT with 99mTc-RM26
Description: One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: whole body study and SPECT with 99mTc-RM26
Description: One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT04789408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KITE-222
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Study: NCT05437601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astaxanthin Oral Capsule
Description: 12 mg oral astaxanthin daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo identical to astaxanthin
Study: NCT05183789

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of serum levels of IL-6 and IL-8
Description: Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of serum levels of IL-6 and IL-8
Description: Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).
Study: NCT05618808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN9933
Description: Participants will receive a single dose of REGN9933 by IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixiban
Description: Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
Study: NCT05138744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral activation using virtual reality
Description: The investigators will encourage behavioral activation (increase in the number and time of conducted activities) situating the person in motivating situations using virtual reality
Study: NCT05324683

Intervention type: OTHER
Intervention: No intervention planned
Description: No intervention planned; study is observational
Study: NCT05850728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-ART
Description: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-ART
Description: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-ART
Description: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-ART
Description: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-ART
Description: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
Study: NCT05378477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X92001752
Description: The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RID Super Max Solution
Description: RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nix Crème
Description: Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pouxit Végétal
Description: Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.
Study: NCT06160817

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative sharp debridement
Description: The debridement method for all patients, regardless of the assigned sequence, will involve the removal of non-viable tissue from the ulcer bed, edges, and perilesional skin using a scalpel (No. 3) with a No. 10 and/or No. 15 blade, along with Adson forceps and straight dissecting forceps.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative sharp debridement
Description: The debridement method for all patients, regardless of the assigned sequence, will involve the removal of non-viable tissue from the ulcer bed, edges, and perilesional skin using a scalpel (No. 3) with a No. 10 and/or No. 15 blade, along with Adson forceps and straight dissecting forceps.
Study: NCT04940819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application for Dietary Management
Description: A mobile application developed by a multi-disciplinary team will be used in the dietary management of CKD patients. The application is patient orientated. It has 4 core features including food searching, dietary logging, personalized key nutrient intake feedback and patient-caregiver interaction.
Study: NCT06189885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin with Daptomycin
Description: For patients randomized to receive daptomycin (8 mg/kg), the drug will be administered in a 50 cc bag, accompanied by a 500 cc bag of normal saline within 60 minutes before surgical incision and discontinued after 24 hours postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin with vancomycin
Description: Then vancomycin (15 mg/kg) will concurrently be given and completed within 60 minutes before surgical incision and discontinued after 24 hours postoperatively9. Patients in the vancomycin arm will receive this drug in a 50 cc bag accompanied by a 500 cc bag of normal saline.
Study: NCT06085495

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mechanical thrombectomy (PMT)
Description: After the establishment of the pathway, Angiojet (Boco, USA) was used to infuse urokinase into the blood vessels of the thrombotic segment. After waiting for 15 minutes, mechanical thrombectomy was performed. After thrombectomy, the effectiveness of thrombectomy was evaluated through angiography. For residual thrombi, repeated thrombectomy was performed, with a maximum thrombectomy volume of 480ml. After thrombectomy, antegrade angiography of the dorsal vein of the foot was performed again. If iliac vein stenosis was found to be greater than 50%, Then, Mustang balloons (Boko, USA) that match the normal blood vessel diameter are used for dilation. If the residual stenosis after dilation is greater than 30%, Wallsten stents that match the normal blood vessel diameter are inserted (Boko, USA). After all operations are completed, a dorsalis pedis venography is performed again to evaluate the thrombus burden and calculate the immediate thrombus clearance rate and thrombus clearance level.
Study: NCT06401746

Intervention type: DEVICE
Intervention: Gastric Alimetry
Description: The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
Study: NCT05931432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Well-Being Intervention
Description: The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions. The content of monthly text messaging resources and discussion topics for the peer-support groups will be informed by the Aim 1 qualitative findings.
Study: NCT06349356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light with C.STIM device
Description: 4 flashes per treatment session

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intense pulsed light with C.STIM device
Description: 4 flashes per treatment session
Study: NCT05418751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Participants will received a manual therapy protocol consisting of the following techniques: manipulation of the occipito-atlanto-axial joint (C0-C1-C2), suboccipital inhibition technique, manipulation of the thoracolumbar hinge (T12-L1), global manipulation of the bilateral pelvis, global abdominal hemodynamic technique, functional technique of the pelvic diaphragm and stretching of the lumbopelvic musculature.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Participants will receive light contact on the same points and for the same amount of time as the experimental group, with no intention to treat.
Study: NCT05150977

Intervention type: OTHER
Intervention: Polysomnography
Description: Reviewing collected data
Study: NCT04875299

Intervention type: OTHER
Intervention: The study is observational
Description: The study is observational
Study: NCT06433557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Description: For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.
Study: NCT05689775

Intervention type: PROCEDURE
Intervention: Reconstruction with robot-assisted rectus abdominis muscle flap
Description: Reconstruction of perineum and/or vagina with robot-assisted rectus abdominis muscle flap.
Study: NCT05885243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: will be given once a week, total 5 sessions ofESWT+ home exercises program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: will be given once a week, total 5 sessions ofESWT+ home exercises program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customized insoles
Description: Will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customized insoles
Description: Will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combined ESWT and custtomized insoles
Description: Will be given once a week, total 5 sessions of ESWT+ home exercise program. Also, simultaneous insoles will be provided. Insoles will be used for 12 weeks.
Study: NCT04809324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gross examination of the resection specimen
Description: measurement of the surgical margin by the operating surgeon using sterile scale, margins \<7mm will be revised on table

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frozen section
Description: frozen section evaluation of the specimen by the pathologist
Study: NCT06250959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab Injection [Blincyto]
Description: Reduced-intensity chemotherapy followed by Blinatumomab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: HyperCVAD regimen
Study: NCT05490342

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
Description: Blood test to value the antibody response to vaccination

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
Description: Blood test to value the antibody response to vaccination
Study: NCT05029713

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)
Description: The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off \<27 Kg in men and \<16 Kg in women and a standardized muscle mass cut-off \<0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)
Description: The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off \<27 Kg in men and \<16 Kg in women and a standardized muscle mass cut-off \<0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.
Study: NCT05050240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling Vest Procedure
Description: A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar_CoolFlow_Manual.pdf.~Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting overnight
Description: Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
Study: NCT05133349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
Study: NCT05487196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine belongs to the drug classification of antihypertensives

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine belongs to the drug classification of sedatives

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
Study: NCT04682860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine N Butylbromide
Description: Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of normal saline injection as placebo
Study: NCT05387876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D intervention
Description: Nordic Naturals vitamin D gummies (1000 IUs/gummie), 4 gummies per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Organic gummie candies (no vitamin D), 4 gummies per day for 12 weeks
Study: NCT06347328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echo-guided infiltration
Description: the subjects will receive their injection in the ultrasound room. a glucocorticoid injection is given at the time of consultation, using anatomical ultrasound scan to guide needle placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-echo-guided infiltration
Description: the subjects will receive their injection in the ultrasound room.~a glucocorticoid injection is given at the time of consultation, using anatomical landmarks to guide needle placement.~The investigator simulate an ultrasound scan with a film shown on the screen.
Study: NCT05817162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the without affecting the motor ones. Ropivacaine comes as solution for injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: temporomandibular joint arthrocentesis
Description: Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: temporomandibular joint arthrocentesis
Description: Temporomandibular arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRP injection
Description: Platelet-Rich Plasma (PRP) is an orthobiological adjuvant treatment. PRP has properties to restore intra-articular hyaluronic acid, increases glycosaminoglycan chondrocyte synthesis and balances joint angiogenesis. It is often used as a viscosupplement in TMJ arthrocentesis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate solution
Description: Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Lactate solution
Description: Ringers lactate solution is used during arthrocentesis to wash out the joint inflammatory cells and to release the stuck disc phenomenon.